Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A venture round brings in $6mm for OvaScience

Executive Summary

Newly formed female infertility treatment company OvaScience has raised $6mm through its Series A venture round from Longwood Fund and Bessemer Venture Partners. The company was created to develop AUGMENT (AUtologous Germline Mitrochondrial ENergy Transfer) to improve the success of in vitro fertilization. AUGMENT involves the injection of a woman’s own egg-precursor cells (obtained from ovarian tissue) into eggs to revitalize the mitochondria that typically declines with age.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies